Biomarker levels in peri-implant crevicular fluid of healthy implants, untreated and non-surgically treated implants with peri-implantitis

Aim To compare biomarker levels in peri-implant crevicular fluid (PICF) of healthy implants with levels in PICF of implants with peri-implantitis (before and after non-surgical treatment).

Materials and methods Samples were taken from 20 healthy implants (n = 17 patients) and from 20 implants with peri-implantitis (n = 19 patients) before and 3 months after non-surgical treatment using the Airflow Master Piezon(R) (EMS). A Luminex (TM) assay was used to evaluate pro-inflammatory and anti-inflammatory cytokines IL-1 beta, TNF-alpha, IL-6 and G-CSF, collagen degradation enzyme MMP-8, chemokines MCP-1 & MIP-1 alpha/CCL3, bone markers OPG and sRANKL and interferon-gamma. Clinical and radiographical characteristics were assessed. A Mann-Whitney U and Wilcoxon signed-rank test analysed between- and within-group differences.

Results IL-1 beta and MMP-8 levels were found significantly elevated in implants with peri-implantitis (p = .007; p =

Conclusion Implants diagnosed with peri-implantitis have higher levels of IL-1 beta and MMP-8 in PICF compared to healthy implants. Non-surgical therapy did not influence the inflammatory immune response.